Summary
Vertex Pharmaceuticals Inc. reported a significant turnaround in its financial performance for the first quarter of 2017 compared to the same period in 2016. The company achieved a net income of $247.8 million, a substantial improvement from a net loss of $41.6 million in Q1 2016. This turnaround was driven by a nearly 80% increase in total revenues, reaching $714.7 million, largely fueled by a substantial $232.5 million in collaborative revenues from a new agreement with Merck KGaA, alongside a 22% growth in net product revenues from its key cystic fibrosis (CF) drugs, ORKAMBI and KALYDECO. Key drivers for the revenue growth include strong product sales from ORKAMBI, which increased by 32%, and KALYDECO, up 9%. The company also announced positive Phase 3 clinical trial results for tezacaftor in combination with ivacaftor, paving the way for potential regulatory submissions. Despite increased operating expenses, primarily in research and development and restructuring, Vertex demonstrated robust profitability. The company maintained a healthy liquidity position with over $1.4 billion in cash, cash equivalents, and marketable securities, positioning it well to fund ongoing operations and development programs, including a pending acquisition of CTP-656.
Financial Highlights
50 data points| Revenue | $714.72M |
| Cost of Revenue | $46.99M |
| Gross Profit | $667.73M |
| R&D Expenses | $273.56M |
| SG&A Expenses | $113.33M |
| Operating Expenses | $443.88M |
| Operating Income | $270.84M |
| Net Income | $247.76M |
| EPS (Basic) | $1.01 |
| EPS (Diluted) | $0.99 |
| Shares Outstanding (Basic) | 246.02M |
| Shares Outstanding (Diluted) | 248.70M |
Key Highlights
- 1Reported a significant net income of $247.8 million, a substantial improvement from a net loss of $41.6 million in the prior year's quarter.
- 2Total revenues surged by 80% year-over-year to $714.7 million, primarily driven by a $232.5 million upfront payment from a new collaboration with Merck KGaA.
- 3Net product revenues increased by 22% to $480.6 million, with ORKAMBI sales growing 32% to $294.9 million and KALYDECO sales growing 9% to $185.7 million.
- 4Announced positive Phase 3 clinical trial results for tezacaftor in combination with ivacaftor, with plans to submit regulatory applications in the US and Europe in Q3 2017.
- 5Operating expenses increased by 8% to $443.9 million, driven by higher R&D and SG&A costs, alongside increased restructuring expenses.
- 6Maintained strong liquidity with $1.41 billion in cash, cash equivalents, and marketable securities as of March 31, 2017.
- 7Entered into an asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals for $160 million, subject to closing conditions.